0 Items
Select Page

Streptococcus pneumoniae

Streptococcus pneumoniae is a major cause of morbidity and mortality, globally causing more deaths than any other infectious disease. At highest risk are the smallest children and elderly, with approximately one million children below 5 years of age dying, annually (CDC). Pneumococcal diseases range from mild respiratory tract mucosal infections, such as sinusitis, to more severe diseases such as pneumonia, septicaemia and meningitis.

The Native Antigen Company are committed to supporting research into Streptococcus, offering specific monoclonal antibodies to this bacterium.

Streptococcus Background

Streptococcus pneumoniae is a lancet-shaped, gram-positive, facultative anaerobic bacterium. In humans, S. pneumoniae primarily colonizes the nasopharynx and transmission occurs from person-to-person via respiratory secretions from patients infected wit, S. pneumoniae, and from healthy carriers. In susceptible individuals, the bacteria can spread to the lower respiratory tract, the inner ear or sinuses, to cause a range of illnesses, referred to as pneumococcal disease.

Worldwide, S. pneumoniae is the major cause of pneumonia, sepsis, and meningitis and the leading cause of community-acquired pneumonia in young children and the elderly.

Streptococcus pneumoniae Antigens

The Native Antigen Company are pleased to offer a Streptococcus pneumoniae native lysate for use in the development of immunoassays.

Streptococcus pneumoniae Antibodies

The Native Antigen Company are pleased to offer a pair of monoclonal antibodies that are specific to Streptococcus pneumoniae, which are suitable for use in the development of immunoassays.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Why We Need Antigen and Antibody Tests for COVID-19

RT-PCR is the workhorse of viral diagnosis and has been invaluable in COVID-19 case confirmation and isolation guidance. However, while fast and sensitive, PCR suffers from some inherent drawbacks that limit it to diagnosis during the acute phase of infection. To...

Gonorrhea: What’s Currently in the Clinical Pipeline?

This article was written by our friends at Infectious Diseases Hub, a free-to-access website that aims to deliver up-to-date, essential research and information on all aspects of microbiology, virology, mycology and parasitology – from bench to bedside....

Novel Coronavirus Antigens Now Available

The Native Antigen Company is now offering recombinant S1 and S2 glycoproteins for SARS-CoV-2 (Covid-19) in response to urgent demand. These reagents are suitable for use in basic research and the development of diagnostics and vaccines.These antigens have been...

The Why and How of Protein Conjugation

In this blog, Lead Assay Development Scientist, Toni Ertl discusses the basics of protein conjugation and introduces our new range of conjugation kits for the labelling of antigens and antibodies.Detecting Proteins If you’re trying to detect or measure the presence...

Going Viral: Why We Need New Diagnostics For a Safe and Effective Dengue Vaccine

This article is taken from European Biopharmaceutical Review January 2020, pages 44-46. © Samedan Ltd.The Dengue VirusDengue is the world’s most prevalent and consequential arboviral disease. Current estimates indicate that as many as 390 million dengue infections...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

11 + 12 =

Live Customer Feedback

Join our mailing list

* indicates required